These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25996489)

  • 21. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically relevant drug interactions between statins and antidepressants.
    Palleria C; Roberti R; Iannone LF; Tallarico M; Barbieri MA; Vero A; Manti A; De Sarro G; Spina E; Russo E
    J Clin Pharm Ther; 2020 Apr; 45(2):227-239. PubMed ID: 31587356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-drug interactions that interfere with statin metabolism.
    Hirota T; Ieiri I
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.
    Yang Y; Li P; Zhang Z; Wang Z; Liu L; Liu X
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites.
    Zhang T
    Eur J Pharm Sci; 2015 Sep; 77():216-29. PubMed ID: 26116278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
    Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological comparison of the statins.
    Klotz U
    Arzneimittelforschung; 2003; 53(9):605-11. PubMed ID: 14558433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.
    Chu X; Chan GH; Houle R; Lin M; Yabut J; Fandozzi C
    AAPS J; 2022 Mar; 24(3):45. PubMed ID: 35314909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of Drug-Drug Interactions Between Warfarin and Statins.
    Shaik AN; Bohnert T; Williams DA; Gan LL; LeDuc BW
    J Pharm Sci; 2016 Jun; 105(6):1976-1986. PubMed ID: 27103011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs.
    Lee W; Koyama S; Morita K; Kiriake A; Kikuchi R; Chu X; Lee N; Scialis RJ; Shen H; Kimoto E; Tremaine L; Ishiguro N; Lotz R; Maeda K; Kusuhara H; Sugiyama Y
    AAPS J; 2020 Oct; 22(6):133. PubMed ID: 33063163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model.
    Varma MV; Bi YA; Kimoto E; Lin J
    J Pharmacol Exp Ther; 2014 Oct; 351(1):214-23. PubMed ID: 25107633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments.
    Watanabe T; Kusuhara H; Watanabe T; Debori Y; Maeda K; Kondo T; Nakayama H; Horita S; Ogilvie BW; Parkinson A; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2011 Jun; 39(6):1031-8. PubMed ID: 21383204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
    Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
    Waters NJ
    Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling.
    Dong J; Prieto Garcia L; Huang Y; Tang W; Lundahl A; Elebring M; Ahlström C; Vildhede A; Sjögren E; Någård M
    Clin Pharmacol Ther; 2023 Oct; 114(4):825-835. PubMed ID: 37376792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.